SHR-A1912

SHR-A1912 is an investigational agent whose form is not stated in the registry developed by Suzhou Suncadia Biopharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06929624 (A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma), in diffuse large B-cell lymphoma. The largest, NCT06929624, plans to enrol 280 participants with primary completion expected 2027-03. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.